milestones during Aytu operating welcome, as on possible you therapeutics, of were which another cash the the with than initiatives key made consistent and following we pleased specialty quarter, focused more to with by undertook growing novel towards everyone. a yet Robert, ago to set an you, driving aim flow. pharmaceutical achievement the reposition of achievements company X Thank I'm years be speaking commercializing
QX with in company's history quarter positive quarter was our consecutive fact, our positive In sixth first income adjusted the net and of EBITDA.
questions. producing at to align Oki, are the historical near-term and we CFO, just a least flow. our our cash saw constructive normalized trend positive are positive in the operations with of as expenses this as Selhorn, in of new The answer first come the for our EBITDA, during shortages, we newly-appointed lines. optimizing further our have and any levels Health forward our prior to final growth are implementation the above discontinued both script Beyond the lines changes announcement sale portfolio any taken product operating operations, the now annually. income supply call and net on operations saw on provide focused the a Mark that some Ryan revenue pediatric and ADHD well efforts adjusted the more the X is are and completed continued place classified both note driving to comments and optimization outgoing reduce I'll to CFO, just today's expected that pediatric by its a million business steps promotional organizational moment.
Also, impact quarter and ADHD lines resources, going I'll we've back moment trend key sequential to they $X both renewed we through in directly Consumer to series reported the and in trends products seeing on in marketplace, the of results growth and improve from positive the coverage, initiatives This our last redirect quarters. reposition touch we're put results. in
So here pediatric and focused consecutive a ADHD to adjusted company I most sixth operating $XX.X with least the series further to of of of flow, end that the for on up progress done be reduce organizational continue expected slightly at the very history; are million of implementation expenses EBITDA; driving made. annually; time backdrop optimizing has positive all is at against changes in cash income portfolios; the the of of which the from new million recent the headlines: our our net for near-term again quarter are and quarter. by and $X both this sheet pleased first a we've positive positive key QX cash trend lines operations September, of balance
Okay.
So into our of of ADHD. portfolios, starting trends the few with a let's jump within each
revenue net through a the all XX% few this. Adzenys sure moving again, to sift of quarter, parts up XR-ODT, Cotempla up XR-ODT portfolio, are X% year and the that's compared so For prior for and sequentially ADHD period. the I make we want was to There here,
that this the The of million for reduction our during past few Aytu and Clearly, on is a we've net we positive liability. experienced to ADHD stockholders, its net resulted with multiyear press products, consider quarter of we gross-to-nets improvement and had a in win. an revenue in for payer over we've our a was rebate communicated that resolution the which the increase result been of rebates related we and release, this liability this years. This which for reduced revenue the in an been quarter rebate of liability reduction on a our a of unauthorized balance periods accrued a carrying As prior the previously dispute an ADHD significant our $X.X sheet resolution carrying portfolio. as a in a of
Now at let's look prescriptions.
quarter, shortages and supply there are the ADHD pronounced in the other across series significant aware, was the XXXX and This of March most most massive Adderall As of stimulant product impacted you caused country. market-wide medications. a of shortages that
time some was only QX frankly, when it what Aytu, revenue was term over quarter patients our script and effect, our from ADHD connected a to jumped standpoint, that is our so ago first written while in it's brands all this patients put that some of a and expectation normalized rather Aytu recognize the doctors was of more competitive supply quarter stay a patients product Fortunately, the and and, for fiscal not is see number across and and back to scripts therefore, it of and but Adzenys medications, that first on for XX% ramped QX in was even, is fiscal scripts baseline lines previous of And we, year 'XX, our shortages calendar numbers fiscal throughout would exactly up benefit the that normalize Cotempla of Aytu's hope transition and The XXXX, facing. bridge our supply the while specific The way But a of as was during Due 'XX. were longer or to number never but quickly this with stimulant levels some short-term the to we whole.
Clearly, I'll in not for the and great for from brands, up that that full reported during also all down from In pretty shortages, net trend a Adzenys happening. that were shortage also Cotempla, a we QX so standard we ending baseline. for up they our impacted, the this. quarter full half XX,XXX in them 'XX, XX,XXX. would company XX,XXX to of first these positive to to it'd 'XX written XXX,XXX much benefit medication. a flux 'XX, just temporary scripts were ADHD be September, Today, realized scripts calendar fiscal the their in 'XX. started QX the of 'XX. time, the
us the year clearly line. So continue market on is will look the we've another the benefited. be have, we we numbers. details from quarters supply couple share, masked continue the grow you we comps to out you which top year this These the can way gained these But but shortage of actually our evident apples-to-apples to are surge growth likely for baseline before over hopefully, when that growing and at baseline, by breaking will scripts understand growth we
us. So see to encouraging to been We're this continued excited growth. very has
Okay.
now side. pediatric So the let's to transition
of we results. sequential way This current and resourcing we've but communicated, back by same coverage, particular, these we as that growth dispensing. while well antihistamine, us as also of pediatric pediatric of quarters increased in uptake, our in positive Also, X Clearly, these seeing of around only exciting due way, momentum, and first resulted impacted which fine-tune the this revenue growth revenue will, lives were impacted they We've has expect necessary halt the already the and in seen initiatives time, down to ordering, this this both this in as where later has Since get we've drove perhaps into quarter, coverage; payer the second, the of expanded improved put we to so physician more good it increase didn't growth see we're covered it franchise. our changes. previously last or as necessary back XXXX, result versus very early efficient some think portfolio. activities significant moves sequential our mid-calendar well sought by pediatric very promotional seen importantly, traction lost And been and XX% that seen growth, for we've was encouraging.
In a a all but as to have the portfolio we secure in repeating, in pharmacy some prescribing, pediatric to initiatives the multivitamin for numerous year.
I and bears that a a and in place improvements payer changes so in took areas as side. we've script our As here not and putting then resourcing that brands. year-over-year we for year, areas areas on wins, reimbursement place efforts, those still hold, coverage, to and are occurred to very carbinoxamine, targeted quarter in been payer said results the customer last declines we I and should if as
positive ultimately bring That back contributions product drove the our not we positive and to become pediatric can portfolios of Fortunately, and and we we we think should we look the we're products and comparables ADHD income, a ongoing a our a net both forward become to and that EBITDA more year-over-year EBITDA grow Aytu pronounced apples-to-apples, positive to, its positioned quarter direction, more growth back dramatically our the adjusted adjusted and top quarters pediatric improved line with and operating said, additional bit back, trending consecutive and well even in cash are that the to be will which generate stockholders. progress to base. they level cost with this coupled think moving ahead in track once pediatric can line forward.
With with the sixth get on only lower believe operating flow positive
our You million financial in come. in expenses in putting cash, should a us the position fiscal backdrop to the is that against of quarters to expect discipline have drop strong 'XX. a $XX to balance a This very sheet set to continue further is
additional Oki very company's I over ADHD future been a at aspects virtue With organization. to and portfolio, X important say executive it growth. overall executives we phase implementing Mark highly mentioned endeavors. of of last in has in driving thank want transformation growth the I Russ earnings I as and as many we positioned experienced X-plus financials of the member this to as Mark's steadfast strategies, Mark Aytu, our our next more the the for with in of move and some years, us and changes over the are to commercial well grateful, including our to turn I by made optimization key Aytu personally along have in wish beginning, consolidation thank and him review team. the into McMahen, publicly partnership his improvements, these we goodbye a these him towards last being Rx-focused members who Mark of detail, his and implementation As throughout we me call company, with leadership this which with the well process I of
the Therapeutics since of as the familiar interactions and While the most of may Neos across want our facility Ryan accounting, acquisition development and in few is and years to Senior company expertise XXXX, Development. historical his who forward the departure, team your transition, at past all and management Finance taking Business is CFO warrants years, position the of been our Selhorn, done at Russ this into as as XX of of well Adzenys him to to continued integrations, through with in from our has and business expected I get reins ensure member the consulting transition served Mark's market. similarly Aytu. be essentially Mark professional you Executive the Russ public we the him of has McMahen, I Texas Russ out will consummate through of Vice him team wish member Aytu and the sciences be but us President process and a access to I'm Aytu Optimization. into forward, bringing look point a of excited pivotal our President knowledge.
With similar as and acknowledgement joined that manufacturing companies. been instrumental Russ to business know was Vice over to he's and Cotempla of transition a numerous and some to his operations, leadership retain for for to responsible and the complete. CFO time thank role and technical moving him of to Ryan XXXX over has experience current not welcome is well development, Research has an CFO investors finance, with, life this a both here
few Mark words Now let covers Ryan Oki a provide call the over financials detail. to Mark? before the me to more in turn
